Fitusiran Delay Dents Sanofi’s Hemophilia Challenge

Company Still Aiming For Universal Therapy

 
• By Andrew McConaghie
  
Sanofi Lyon
A move to target hard-to-treat blood disorders is part of Sanofi's strategy, but has been hit by numerous trial delays. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Therapeutic Category